---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000115"
form_type: "8-K/A"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T09:57:11.185986+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Salarius amends merger with Decoy; legacy holders diluted to 7.6%

## Summary
- Effective ownership post-merger: Salarius legacy holders 7.6%, Decoy holders 92.4% (pre-Qualified Financing).
- Salarius valuation reduced from $4.6M to $2.31M in Amendment 2; Decoy valued at $28M.
- Qualified Financing requires minimum $6M; expected $8M from 1,470,588 shares at $5.44/share.
- Amendment 4 removes threshold for anti-dilution adjustments; applies until Nasdaq listing & shareholder approval.
- Merger accounted for as reverse asset acquisition with Decoy as accounting acquirer.

## SEC filing metadata
- accession: 0001615219-25-000115
- form_type: 8-K/A
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000115/0001615219-25-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000115/flks-20250822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000115
- JSON: https://secwatch.observer/filing/0001615219-25-000115.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.